-+ 0.00%
-+ 0.00%
-+ 0.00%

BriaCell Analysis Links Circulating Immune Biomarker to Survival in Metastatic Breast Cancer

PUBT·10/23/2026 11:31:38
Listen to the news
BriaCell Analysis Links Circulating Immune Biomarker to Survival in Metastatic Breast Cancer
  • BriaCell Therapeutics presented metastatic breast cancer biomarker findings at ESMO 2026, linking changes in circulating immune cells’ PD-L1 expression to survival outcomes.
  • The pooled analysis included 111 previously treated patients receiving immunotherapies, including participants in the earlier Phase 1/2 Bria-IMT study.
  • Measurements at roughly three months were associated with progression-free and overall survival; pretreatment measurements showed no significant association.
  • The findings support further evaluation of CAML PD-L1 to identify patients likely to benefit from immunotherapy, but require validation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230730PRIMZONEFULLFEED9851854) on October 23, 2026, and is solely responsible for the information contained therein.